Rilparencel is under clinical development by Prokidney and currently in Phase I for Unspecified Genito Urinary Disorders. According to GlobalData, Phase I drugs for Unspecified Genito Urinary Disorders does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Rilparencel LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Rilparencel overview
Prokidney overview
Prokidney is a clinical research and biotechnology company. The company focuses on developing a transformative proprietary cell therapy platform with the potential for treating chronic kidney disease (CKD) using a patient’s own cells. Its product portfolio includes REACT (renal autologous cell therapy). The company’s service offerings include preclinical research, clinical trials, research and development, drug development, and drug discovery programs. Prokidney technology restores kidney function by using the patient’s own kidney cells to delay and prevent renal replacement therapy and kidney transplant. Prokidney is headquartered in Winston-Salem, North Carolina, the US.
For a complete picture of Rilparencel’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
